News and Media

Latest News Release
01/31/2024

Transaction creates increased clinical and economic value for 11,500 specialty providers, including more than 7,000 physicians across 1,200 independent physician practices Transaction creates...

Top feature box IMAGE ONLY - COMPANY NEWS

Press Releases

Cardinal Health to Webcast Discussion of Third-Quarter Results for Fiscal Year 2021 on May 6
03/30/2021

DUBLIN, Ohio, March 30, 2021 /PRNewswire/ -- Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2021 on May 6 prior to the opening of trading on the New York Stock Exchange. The company will webcast a discussion of these results beginning at 8:30 a.m. Eastern.

To access the webcast and corresponding slide presentation, go to the Investor Relations page at ir.cardinalhealth.com. No access code is required.  Presentation slides and a webcast replay will be available until May 5, 2022.

About Cardinal Health
Cardinal Health is a distributor of pharmaceuticals, a global manufacturer and distributor of medical and laboratory products, and a provider of performance and data solutions for health care facilities. With 50 years in business, operations in more than 40 countries and approximately 48,000 employees globally, Cardinal Health is essential to care. Information about Cardinal Health is available at cardinalhealth.com.

Media: 

Sarah Shew


(614) 553-3401


Sarah.Shew@cardinalhealth.com



Investors: 

Kevin Moran


(614) 757-7942


Kevin.Moran@cardinalhealth.com

 

SOURCE Cardinal Health

More Company News
04/02/2024

The Consumer Health Logistics Center will be located in Central Ohio and serve as a centralized hub for distribution of consumer health products COLUMBUS, Ohio, April 2, 2024 /PRNewswire/ --...

03/26/2024

Cardinal Health (NYSE: CAH) plans to release third-quarter financial results for its fiscal year 2024 on May 2, prior to the opening of trading on the New York Stock Exchange. The company will...

03/15/2024

Cardinal Health (NYSE: CAH) today announced that the company has received approval by the Science Based Targets initiative (SBTi) for its near-term science-based greenhouse gas (GHG) emissions...

02/29/2024

Study reveals impact of dramatic increase in commercially available biosimilars and progress in the areas of patient accessibility and treatment affordability DUBLIN, Ohio, Feb. 29, 2024...

View all company news »